←
Ruffell Lab392 posts
Ruffell Lab avatar

Ruffell Lab

@Ruffell_Lab

Cancer immunology lab @MoffittResearch investigating the role of dendritic cells and macrophages in breast and prostate cancer.

◷ Joined March 2021▧ 9 Photos and videos
Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

Thrilled to share our story out in Cancer Cell, led by the amazing Kay Hanggi (now on the job market). We show that necrotic forms of cell death and the subsequent release of IL1a drives myeloid-based immune suppression in models of breast cancer. (1/11) cell.com/cancer-cell/abstrac…

Cancer Cell avatar
⟳ Ruffell Lab retweeted
Cancer Cell@Cancer_Cell·10 Dec 2024

Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity dlvr.it/TGhVzG

Post attachment
Amanda Lund Lab avatar
⟳ Ruffell Lab retweeted
Amanda Lund Lab@theLundLab·7 Dec 2024

Excited to share our latest by @Triantafyllia14 where we find that IFNg acts as a metabolic switch to prune tumor-associated lymphangiogenesis and unlink immune surveillance and metastasis biorxiv.org/content/10.1101/… #theLundLab

Dr. Patrick Hwu avatar
⟳ Ruffell Lab retweeted
Dr. Patrick Hwu@PatrickHwuMD·7 Dec 2024

#ScienceSaturday ➡️ Did you know that some chemotherapies can enhance the immune response against #cancer?   ❓ How might we potentiate this?   ➡️ @Ruffell_Lab and colleagues from @moffittnews found that the necrotic cell death induced by #chemotherapy releases IL-1 alpha which induces immunosuppressive myeloid cells. Inhibiting IL-1 alpha in combination with chemotherapy enhanced antitumor responses. ‼️ This may be a promising approach for future clinical trials. 🔗 Here’s a link to the full study- cell.com/cancer-cell/abstrac… @Cancer_Cell

Post attachment
Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

Finally, it is unclear if there are divergent roles for tumor IL1a versus host IL1B due to different expression patterns or methods of release. (10/11)

Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

Questions remain regarding the type of necrotic death necessary for IL1a release, especially in the context of therapy, and which immune or strongly populations are responding to IL1a. (9/11)

Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

IL1R-deficient tumors also displayed enhanced response to chemotherapy, highlighting an interaction between dying tumor cells and their remaining neighbors. (8/11)

Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

We then tested if IL1a-deficient tumors were more sensitive to chemotherapy or chemoimmunotherapy, and found improved responses to both. This included an additional model of TNBC. Treatment efficacy was similarly enhanced by the use of an IL1a neutralizing antibody. (6/11)

Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

There was also a striking shift towards CXCL9 expression and away from SPP1 expression, which has been shown to correlate with positive outcomes by @PittetLab (5/11) science.org/doi/10.1126/scie…

Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

Knocking out Il1a in tumors produced only minimal change in tumor growth, but improved T cell effector function. Critically, macrophages isolated from IL1a-deficient tumors completely lost their suppressive capacity. (4/11)

Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

In vitro studies showed necroptosis induced chemokine expression by tumor cells (even with MLKL alone), with the supernatant being highly potent when added to live cells. Chemokine expression was MyD88-dependent and was blocked by inhibiting IL1R or IL1a, but not IL1B (3/11)

Ruffell Lab avatar
Ruffell Lab@Ruffell_Lab·24 Nov 2024

The project started with Kay wanting to understand how necroptosis within tumors would promote anti-tumor immunity. However, when using genetic tools to induce necroptosis in PyMT mammary tumors he found they grew faster with reduced T cell effector function. (2/11)

Renato Ostuni avatar
⟳ Ruffell Lab retweeted
Renato Ostuni@OstuniLab·22 Nov 2024

People, the IL-1 pathway is SO RELEVANT in cancer 🔥🔥 IL-1a released from dying tumor cells dampens anti-tumor immunity by recruiting immune suppressive myeloid cells - this limits efficacy of chemo and ICB by Brian Ruffel in @Cancer_Cell cell.com/cancer-cell/fulltex…

Cancer Cell avatar
⟳ Ruffell Lab retweeted
Cancer Cell@Cancer_Cell·21 Nov 2024

Online Now: Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity dlvr.it/TGJwxg

Post attachment